Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$57.50 USD

57.50
872,799

+0.19 (0.33%)

Updated Oct 16, 2024 11:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates

The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.

Indrajit Bandyopadhyay headshot

FDA Opposes Dilution of COVID-19 Vaccine Doses: Here's Why

The FDA is against any changes to the approved dosing regimens for Pfizer (PFE)/BioNTech (BNTX) and Moderna's (MRNA) coronavirus vaccines as demanded by some experts.

Will Walgreens Boots' (WBA) Retail Arm Be Dull in Q1 Earnings?

Walgreens Boots' (WBA) retail pharmacy international sales are likely to remain dull in Q1 on difficult market scenario in the United Kingdom.

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Sweta Killa headshot

U.S. Dollar Sees First Drop Since 2017: ETFs & Stocks to Buy

The super-easy policies by the Fed and the central government as well as a series of vaccine development have pushed the U.S. dollar down.

Moderna (MRNA) Raises COVID-19 Vaccine Production Target

Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.

Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

Tech Finishes as the Strongest Sector in 2020

Tech Finishes as the Strongest Sector in 2020

Mark Vickery headshot

Markets Pick Up in 2021 Right Where They Left Off

The Dow is up more than 110 points, the Nasdaq +60 and the S&P 500 +15. It appears there is more appetite at the start of the year to shoot for new all-time highs in the market.

Nilanjan Choudhury headshot

5 Momentum Stocks Bargain Hunters Would Love Chasing

To tap the market's rally, it will be prudent to invest in momentum stocks that are still cheap. Our choices are Winnebago Industries (WGO), Fiat Chrysler (FCAU), FedEx (FDX), Williams-Sonoma (WSM) and Lennar (LEN).

Anindya Barman headshot

5 Little-Known Stocks Under $20 Analysts Recommend Buying

We recommend a few lesser-known stocks that hold promise for high returns this year. ADTN, AMEH, ATEC, DFIN and DGII fit the bill.

Sanghamitra Saha headshot

Top ETF Stories of Fourth-Quarter 2020

The year 2020 as a whole could easily be attributed to the COVID-19 outbreak.

Sweta Killa headshot

5 Big ETF Stories of 2020 Worth Watching in 2021

We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.

AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK

AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.

Sweta Killa headshot

4 Best Performing Sector ETFs of December

Despite the surge in coronavirus cases, December has been kind for the U.S. stock market with the major indices enjoying a historic rally.

Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results

Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.

The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

Nilanjan Choudhury headshot

5 Factors Indicating That Oil is Poised for a Run-Up in 2021

As a proof of the improving energy environment, refining biggies like Marathon Petroleum (MPC) and Phillips 66 (PSX) experienced sequential increase in utilization during the third quarter.

Sweta Killa headshot

Wall Street Stories That Hit Headlines in 2020

With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.

Kinjel Shah headshot

5 Biotech Stocks That Have Gained More Than 200% in 2020

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

    Sandip Chakraborty headshot

    5 Stocks That Could Hit Several New Highs in 2021

    Given the upbeat sentiments in the market, FedEx (FDX), Deere (DE), D.R. Horton (DHI), Fortescue (FSUGY) and Fiat Chrysler (FCAU) are expected to give good returns to investors in 2021.

    Sweta Killa headshot

    5 Sector ETFs That Beat the Market in 2020

    With historic twists and turns, 2020 has turned out to be a banner year.

    3 Restaurant Stocks to Gain Big With the Vaccine Rollout

    Restaurant industry is likely to benefit from the vaccine rollout. Following the vaccine rollout, dine-in option should become safe and traffic is likely to increase.

    Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.

    Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.

    6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

    We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.